Industry resources and insights

Sort by year
  • All time
  • 2026
  • 2025
  • 2024
  • 2023
  • 2022
  • 2021
  • 2020 and older
Analysis
19.08.2026
Europe’s First JCAs: Early Signals for Pricing &...

The publication of the first three EU Joint Clinical Assessments (JCAs) provides the first opportuni...

Read more
Articles
10.08.2026
The Hidden Risk in Pharma Pricing: When Poor Gover...

Pricing strategies rarely fail because of one decision. More often, price potential is gradually ero...

Read more
Webinar
05.08.2026
Decoding Germany’s SHI reform practical impl...

Germany’s SHI reform bill removes some of the most significant AMNOG restrictions introduced in 20...

Read more
White Paper
26.07.2026
Conflict-of-interest management rules and implicat...

Executive Summary Rare disease assessments rely on specialist clinical and patient expertise to inte...

Read more
Webinar
22.07.2026
Design Once, Adapt Smartly Aligning NICE and JCA e...

As NICE and EU Joint Clinical Assessment (JCA) requirements increasingly need to be considered in pa...

Read more
Articles
22.07.2026
Defending Price Under HTA Scrutiny: Why Evidence M...

Price ambition is only defensible when the evidence can carry it  Manufacturers can no longer r...

Read more
Load more
Browse by topic
Content type
  • All
  • Analysis
  • Articles
  • Case Studies
  • Checklist
  • Guide
  • Insider Insights
  • News
  • Poster
  • Publications
  • Webinar
  • White Paper
Subscribe
This field is for validation purposes and should be left unchanged.
This field is hidden when viewing the form
Consent

Talk to an expert

Remap Consulting have significant experience working with pharmaceutical and biotech companies in helping them navigate global market access.​

Get in touch